Relugolix Production Cost Reports

The report provides a detailed analysis essential for establishing a relugolix production plant. It encompasses all critical aspects necessary for relugolix production, including the cost of relugolix production, relugolix plant cost, relugolix production costs, and the overall relugolix production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a relugolix production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Relugolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist that competitively blocks GnRH receptors. This rapidly suppresses luteinising hormone (LH), follicle-stimulating hormone (FSH), and sex hormones like testosterone or estrogen. It is effective for hormone-sensitive conditions and approved for advanced prostate cancer in adult men. It lowers testosterone to slow cancer growth and offers convenience as the first oral GnRH antagonist over injectables like leuprolide. It is used in combination with estradiol and norethindrone to treat heavy menstrual bleeding due to uterine fibroids in premenopausal women. Its common side effects include hot flashes, fatigue, diarrhoea, constipation, muscle and joint pain, high blood sugar and triglycerides, weight gain, low libido, insomnia, and low haemoglobin.

The market for relugolix is fuelled by growing incidences of hormone-sensitive diseases. Its utilisation in advanced prostate cancer, uterine fibroids, and endometriosis contributes to its demand. The oral administration for better patient compliance versus injectables like leuprolide and a reduced side effect profile compared to traditional GnRH agonists makes it a preferred choice.

The industrial relugolix procurement is affected by favourable reimbursement policies and payer coverage in developed markets. The regulatory endorsements from the FDA, EMA,  etc., along with dynamic pricing strategies from manufacturers, influence accessibility and bulk purchasing. The ongoing R&D investments in combination therapies with estradiol and norethindrone, and strategic alliances for generic entry post-patent expiry, impact its sourcing.

Raw Material for Relugolix Production

According to the relugolix production plant project report, the key raw materials used in the production of relugolix include 4-nitropropiophenone, ethyl cyanoacetate, triethylamine, and 3-amino-6-methoxypyridazine.

Production Process of Relugolix

The extensive relugolix production cost report consists of the following major industrial production process:

1. By Gewald aminothiophene synthesis: The production of relugolix starts by performing Gewald aminothiophene synthesis. In this process, 4-nitropropiophenone reacts with ethyl cyanoacetate, triethylamine, and sulfur in ethanol to form ethyl 2-amino-4-methyl-5-(4-nitrophenyl)thiophene-3-carboxylate. This is hydrolysed with NaOH to the corresponding carboxylic acid, then activated with CDI in THF for coupling with 3-amino-6-methoxypyridazine to give the amide. This amide is cyclised with diethylpyrocarbonate and aminopyridine, followed by NaOMe treatment to form the thymine-fused thiophen pyrimidine core. This is quaternised at the methyl group with chloroformate under Hofmann conditions and displaced with dimethylamine to give relugolix as the final product.

Relugolix is a white to off-white crystalline powder with a molecular formula of C29H27F2N7O5S and a molecular weight of 623.64 g/mol. It has a melting point of 228 degree Celsius with decomposition and has a density of 1.442 g/cm³. It shows low water solubility but good permeability, suitable for oral formulations. It is a non-peptide small molecule featuring a thieno[2,3-d]pyrimidine-2,4-dione core with 2,6-difluorobenzyl, dimethylaminomethyl, 6-methoxypyridazinyl, and phenyl-methoxy urea substituents. It has 68-71% plasma protein-bound (mainly albumin) and is metabolised primarily by CYP3A, with moderate bioavailability reduced by food. All these physical and chemical properties makes it useful as a receptor antagonist.